Dr. Moore received his training in England. He earned a B.Sc. from Durham University in Molecular Biology and Biochemistry and a Ph.D. in human retroviruses and cancer from Cambridge. His post doctoral research was also in Cambridge, focused on human papillomavirus (HPV) life cycle and vaccines.
Dr. Moore continued his focus on HPV in Vancouver when he joined the GSC at the end of 2003. In early 2005 he took on his current role as Sequencing Group Leader. Genomics has undergone rapid and dramatic technological advances and the GSC has been at the cutting edge of these changes. From capillary sequencing to nanopore sequencing of 100 kilobase reads and from Megabases to Petabases of sequence data generated. These advances have enabled a genome- and transcriptome-wide focus on cancer research that the GSC is actively involved in.
Dr. Moore’s research focus is on cancer genomics and technology development, with a personal interest in cancer-causing infectious agents. One highlight being the Fusobacterium and colo-rectal cancer association (Castellarin et. al. Genome Research 2012) that was named one of the 10 medical breakthroughs of 2012 by Time magazine.
Dr. Moore is fortunate to have been involved in a large number of research projects whilst at the GSC, contributing to impactful publications. He was listed by Clarivate as a “highly cited researcher of 2018” by virtue of being in the top 1% of cited scientists. He is an author on over 170 articles, each with more than 10 citations.
Adjunct Professor, Faculty of Health Sciences, Simon Fraser University
Dr. Moore oversees the sequencing laboratory at the GSC and plays an active role in experimental design for internal and collaborative projects. The sequencing laboratory includes the Illumina platforms and nanopore sequencers, with a total capacity of 80 terabases per month. Dr. Moore also oversees the targeted clinical panel sequencing pipeline which processes 350 samples per month.
Dr. Moore is chair of the technical development committee at the GSC which tests and validates new approaches and protocols in genomics.